Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
This study is ongoing, but not recruiting participants.
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )
First received: December 12, 2011
Last updated: March 10, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||March 2018|
|Primary Completion Date:||October 2016 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||February 8, 2017|